The healthcare sector in Taiwan is currently going through a challenging phase amidst the decreasing number of hospitals, shortage of healthcare professionals and increasing healthcare expenditure due to an increase in the ageing population. These issues are expected to deteriorate further in the future and become detrimental to the healthcare sector’s growth.
Prashant Khadayate, Medical Device Analyst at GlobalData, said: “These issues can be addressed in an effective way and turn the challenges into an opportunity. The medical device industry can use artificial intelligence (AI), big data and the Internet of Things (IoT) to develop affordable and comprehensive healthcare solutions focused on digital health, medical imaging, decision support, and precision medicine, and improve the overall healthcare sector performance.”
In the past two years, Taiwan has seen extensive public and private investment in AI. The Ministry of Science and Technology has invested $515 million to set up four AI centers at prominent Taiwan universities focusing on commercial applications.
GlobalData estimates the Taiwan medical devices market to increase from $2.8 billion in 2018 to nearly $3.7 billion by 2025 due to the growing elderly population and subsequent increase in the demand for healthcare products and services.
Traditionally, Taiwan medical device manufacturers mainly produced and exported mid-to-low-end devices. The country is dependent on imports of high-end medical devices, primarily from the United States and Japan.
In April 2017, the Taiwan government announced to invest $64 million in Taiwan’s medical device industry with the aim of moving it up the value chain. The Industrial Technology Research Institute (ITRI) and some of its partner companies, including iXensor, AmCad BioMed Corporation and Episonica, have already developed advanced medical imaging devices.
Khadayate concluded: “Taiwan’s medical device industry is on the cusp of transition as the government is focusing on developing the country as the ‘Silicon Valley of Asia’ and transforming Taiwan into a ‘Hub of Biotech and Medical R&D in Asia.’ Both these initiatives are expected to create an ideal ecosystem, which will largely benefit the medical device industry. In addition, the high-end medical devices developed in Taiwan offer the same performance but are cost effective compared to their U.S. and European counterparts. Embracing AI in medical devices will not only solve the local healthcare related issues but will also prepare the industry for global opportunities, where currently the U.S. and European companies dominate.”
Four-thousand of the world’s largest companies, including more than 70 percent of FTSE 100 and 60 percent of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s array of data, expert analyses and solutions, all in one platform. GlobalData’s mission is to help clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.